ASCO 2024 | Challenges and opportunities in integrating immunotherapy for uveal melanoma

Suthee Rapisuwon, MD, Georgetown University, Washington, DC, discusses integrating immunotherapy into the adjuvant treatment for uveal melanoma. The study showed promising improvements in distant metastasis-free survival with adjuvant ipilimumab and nivolumab. However, the HCRN MEL17-309 trial (NCT03528408) presents challenges for moving to Phase III trials. International collaboration is essential to confirm findings and address potential biases and adverse events. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.